OR
Therapeutic Areas
Xlife Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Alexipharm Platform | Oncology (Targeted Toxins) | Pre-clinical |
| Aurealis Therapy (AUP-16) | Chronic Wounds / Diabetic Foot Ulcers | Phase 1/2 |
| EpiQMAx Platform | Oncology (Epigenetic Modulators) | Pre-clinical |
| Grey Wolf Therapeutics Programs | Oncology (Immuno-oncology) | Phase 1/2 |
| Prestwick Programs | Rare Diseases (e.g., APDS) | Pre-clinical / Clinical |
| Scailyte Platform | AI-based Diagnostic Analysis | Commercial |
Leadership Team at Xlife Sciences
DM
Dr. Markus Kühni
Member of the Board of Directors
DR
Dr. René G. Bantle
President & Member of the Board of Directors
DM
Dr. Mathias Hothum
Chief Executive Officer (CEO)
DD
Dr. Dirk Pleimes
Chief Medical Officer (CMO)
DS
Dr. Stephan Weiler
Chief Financial Officer (CFO)
DM
Dr. Michael K. O'Neil
Chief Scientific Officer (CSO)
DB
Dr. Bernhard Sixt
Chief Business Officer (CBO)
DJ
Dr. Jochen R. Moehrle
Head of Portfolio Management
DS
Dr. Sarah K. Weber
Head of Corporate Communications & Investor Relations